Ann Biomed Eng
Annals of Biomedical Engineering
0090-6964
1521-6047
Kluwer Academic Publishers-Plenum Publishers
New York


1705506
17053986
9163
10.1007/s10439-006-9163-z
Article


Heart Valve Tissue Engineering: Concepts, Approaches, Progress, and Challenges

Mendelson
Karen

1

Schoen
Frederick J.

fschoen@partners.org

1
2

1
Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA USA 
2
Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115 USA 

12
10
2006

12
2006

34
12
1799
1819
6
2
2006

11
7
2006


© Springer Science&#x002B;Business Media, Inc. 2006

in-vivo
in-vitro
 cell seeding. Lastly, we analyze challenges to the field and suggest future directions for both preclinical and translational (clinical) studies that will be needed to address key regulatory issues for safety and efficacy of the application of tissue engineering and regenerative approaches to heart valves. Although modest progress has been made toward the goal of a clinically useful tissue engineered heart valve, further success and ultimate human benefit will be dependent upon advances in biodegradable polymers and other scaffolds, cellular manipulation, strategies for rebuilding the extracellular matrix, and techniques to characterize and potentially non-invasively assess the speed and quality of tissue healing and remodeling.

Keywords
Heart valve remodeling
Engineered tissue heart valves
Biodegradable scaffold
Decellularized scaffold
Circulating stem cells

issue-copyright-statement
© Biomedical Engineering Society 2006




INTRODUCTION
58
102
103
104
114
178
27
36
74
80
123
14
119
122
176
 This review focuses on the application of tissue engineering technology to heart valves.
127
50
64
146

1
35
68
120
67
TABLE 1.
Design objectives for and characteristics of replacement heart valves.

Feature to optimize
Conventional (Mechanical, bioprosthetic)
Tissue engineered


Closure of leaflets
Rapid and complete
Rapid and complete

Size of orifice area
Less than that of natural valves
Better

Mechanical properties
Stable
Stable

Surgical insertion
Easy and permanent
Easy and permanent

Risk of thrombosis
Yes, especially mechanical valves, which require anticoagulation, causing vulnerability to hemorrhage
No; endothelial surface to inhibit thrombogenesis

Risk of structural dysfunction
Degradation of synthetic materials rare with mechanical valves
Resistant to degradation and calcification


Tissue degradation and calcification of leaflets with bioprosthetic valves


Risk of Infection
Ever present
Resistant to infection

Viability
No
Yes, able to repair injury, remodel, and potentially grow with patient




FIGURE 1.
Specialized ECM enables dynamic aortic valve function. (a) Photograph of the aortic valve in open and closed position (from the aorta). (b) Aortic valve histology emphasizing trilaminar structure and presence of valvular interstitial and endothelial cells. (c) Biomechanical cooperativity between elastin and collagen during valve motion. (d) Schematic depiction of layered aortic valve cuspal structure and configuration of collagen and elastin during systole and diastole. (a) and (b) reproduced by permission from Schoen FJ. “Valvular heart disease: General principles and stenosis,” IN: Cardiovascular Pathology, 3rd Ed, Silver MD, Gotlieb AI, Schoen FJ (eds.), WB Saunders 2001, pp. 402–442; (c) and (d) reproduced by permission from Schoen FJ. Aortic valve structure-function correlations: Role of elastic fibers no longer a stretch of the imagination. J Heart Valve Dis 6: 1–6, 1997.




121
143
1
147
 A successful tissue engineered valve and its components must not only accommodate those deformations but also have ongoing strength, flexibility, and durability, beginning at the instant of implantation and continuing indefinitely thereafter, possibly despite an evolving tissue architecture.
in-vivo
in-vivo
in-vitro
TABLE 2.
Key structural elements of heart valves.

Element
Sub-structure
Function


Extracellular matrix
Collagen
Provides strength and stiffness to maintain coaptation during diastole, when cusp has maximal area


Elastin
Extends in diastole; contracts in systole to minimize cusp area


Glycosaminoglycans
Accomodates shear of cuspal layers, cushions shock during valve cycle

Cells
Interstitial
Synthesize ECM; express MMPs and TIMPs that mediate matrix remodeling


Endothelial
Maintain nonthrombogenic blood-tissue interface; regulate immune and inflammatory reactions

Blood vessels

Few and focal; valve cusps and leaflets sufficiently thin to be nourished by diffusion from the heart’s blood

Nerves

Present, with uncertain function

Other principles
Corrugations
Accordian-like folds in cusps; allows cuspal shape and dimensions to vary with cardiac cycle


Crimp
Microscopic collagen folding, allows lengthening at minimal stress


Anisotropy
Permits differences in radial and circumferential extensibility


Cords
Macroscopic collagen alignment; transfers forces from cusps to aortic wall






HEART VALVE FUNCTION AND STRUCTURE
2
185
87

1
ventricularis
fibrosa
spongiosa
1
145
In vivo
92
93
94

143
1
1
d). During valve opening, elastin stretches during extension of collagen crimp and corrugations. When the valve is closed, the collagen is fully unfolded and the load is shifted from elastin to collagen; elastin restores the contracted configuration of the cusp during systole.
1
1
121
168
169
21
16
17
155
 The reasons for these differences are not yet known.
1
169
1
25
121
168
169
1
121
142
148
99
148
in-vitro
169
177

in-vitro
93
 The need for mechanical stimulation and/or cytokines and potentially other soluble factors for the maintenance of appropriate cellular biosynthetic activity will be an important influence on tissue engineering efforts.

HEART VALVE DEVELOPMENT, MATURATION, ADAPTATION, AND REPAIR
mesoderm
160
106
174
 Growth of the looped heart tube and development of septa leads to the multichambered heart.
endocardial cushions
mesenchyme
30
epithelial-to-mesenchymal transdifferentiation
cardiac jelly
5
124
31
110
5
9
43
78

1
 We demonstrated that fetal valves contain immature activated cells and are dynamic and adaptable structures; the architecture, collagen content, and organization were immature compared with that of adult valves. During valve development and maturation, fetal VIC have a myofibroblast-like phenotype, characterized by expression of α-SMA, MMP-13, and SMemb, and continuously remodel the ECM. The cells become quiescent in the normal valve post-natally, suggesting progressive adaptation to the prevailing hemodynamic environment. Moreover, the cell density progressively decreases (by nearly 90%) throughout life.
121
117
120
in-vitro
in-vivo
118
in-vivo
. Therefore, heart valves respond to environmental change via reversible phenotypic modulation of their resident VICs.

SCAFFOLDS FOR TISSUE ENGINEERING: GENERAL CONCEPTS
scaffold
cells
in-vitro stage
bioreactor
in-vivo stage
2
77
in-vitro
in-vivo
in-vivo
in-vitro
2
in-vivo
in-vivo
3
TABLE 3.
Comparative analysis of scaffolds.


Synthetic scaffolds
Natural scaffolds


Advantages
 Control of material structure and properties (e.g. pore size, stability, degradation rate)
Maintain architecture of the native tissue (potentially valve)


 Easily reproduced
Maintain biological information (e.g., reactive sites, growth factors)


 Resorbable
Potentially resorbable

Disadvantages
 Difficulty in controlling cell adhesion and tissue reorganization
Decellularization may alter physical properties


 Inflammation due to incomplete polymer degradation or lack of biocompatibility
Difficulty of cell penetration into interior


 Space formerly occupied by polymer and its interstices is replaced by fibrosis/scar
May induce immunologic reaction


 Limited perfusion to deep cells
Potential for calcification




FIGURE 2.
Pathway A
in-vitro
in-vivo
in-vitro
in-vivo
modified paradigm
Pathway B
in-vivo
.




Synthetic Scaffolds
41
53
69
83
100

Polyglycolic acid
polylactic acid
48

in-vitro
71
84
85
115

smart
76
79
2
75
N
186
154

92
136

Potential undesirable features of synthetic scaffolds include local tissue inflammation owing to the foreign body reaction and slow and/or incomplete polymer degradation. As the scaffold degrades, the space formerly occupied by a polymer and its interstices is progressively filled by cells and ECM which may eventuate in fibrosis (scar) that poorly resembles specialized native tissue and may contract and distort during maturation. In some cases, cells on the scaffold periphery are healthy and resemble native differentiated parenchymal (i.e., function-specific) tissue whereas cells at the interior become necrotic due to restricted deep delivery of oxygen and nutrients, and removal of wastes.

Natural Scaffolds
178
150
151
171
170
66
97
134
187
187
66
166
in-vitro
97
88
129

54

7
133
182
132
130



CELLS FOR TISSUE ENGINEERING: GENERAL CONCEPTS
in-vitro
in-vivo
2
91
in-vitro
26
2
in-vivo
in-vitro
59
37
95

22
46
164
33
81

56
61
125
173
in-vitro
184
70

113
116
86
90
112
in-vitro
107
65


BIOREACTORS FOR TISSUE ENGINEERING
in-vitro
52
101
158
181
103
161
96
in-vitro
123
 The optimal conditioning protocol depends on numerous parameters such as the sensitivity of the cell phenotype to mechanical cues, the scaffold used, the transfer of the mechanical cues from the scaffold to the cells, and the magnitude and type of mechanical cues.

IN-VIVO
 STUDIES IN HEART VALVE TISSUE ENGINEERING
in-vitro
4
188
in-vitro
in-vivo
in-vivo
TABLE 4.
Representative, animal, and clinical implant studies using seeded and non-seeded matrices.

Study
Scaffold
Cells
Site


In-vitro
 seeding

 (A) Shinoka (1995–96)
Polyglycolic acid (PGA)
Autologous ovine endothelial cells and fibroblasts
Replacement of one pulmonary valve (PV) leaflet in sheep

 (B) Hoerstrup (2000)
Poly-4-hydroxybutyrate (P4HB) coated PGA
Autologous ovine endothelial cells and myofibroblasts
Replacement of all three PV leaflets in sheep

 (C) Steinhoff (2000)
Decellularized pulmonary sheep valves
Autologous ovine endothelial cells and myofibroblasts
PV conduits implanted into sheep

 (D) Dohmen (2002)
Decellularized cryopreserved pulmonary allograft
Autologous human vascular endothelial cells
Reconstruction of the right ventricular outflow tract (RVOT) in a human patient

 (E) Perry (2003)
P4HB coated PGA
Autologous ovine mesenchymal stem cells
in vivo
 implantation

 (F) Iwai (2004)
Poly(lactic-co-glycolic acid) (PLGA) compounded with collagen microsponge
in-vitro
 precellularization
Patch implant in canine pulmonary artery

 (G) Sutherland (2005)
PGA and poly-L-lactic acid (PLLA)
Autologous ovine mesenchymal stem cells
Replacement of all three PV leaflets in sheep

In-vivo
in-vitro
 seeding)

 (A) Matheny (2000)
Porcine small intestinal submucosa
N/A
Replacement of one PV leaflet in a pig

 (B) Elkins (2001)
Decellularized (using SynerGraft treatment) human (CryoValve SG) and sheep pulmonary valves
N/A
SynerGraft-treated and cryopreserved sheep PVs implanted in RVOT in sheep; CryoValve SG human PVs implanted in patients

 (C) Simon (2003)
Decellularized porcine Synergraft valve
N/A
Implanted in RVOT in children





In-Vitro

in-vitro
2
152
153
 Histologic evaluation of the constructs showed development of an ECM, endothelialization of the surface, and scaffold remodeling. While this preliminary experiment showed that a tissue engineered valve leaflet constructed from its cellular components can function in the pulmonary valve position, the resultant engineered tissue heart valve cusps were thicker, stiffer, and less pliable than native valves.
et al.
52
in-vitro
in-vitro
in-vitro
in-vitro
in-vivo
52
in-vivo
, probably regulated by the mechanical environment.
l
in-vitro
in-vivo
6


In-Vitro

28
72
141
163
in-vitro
10
158
162

131
in-vivo
95
FIGURE 3.
A representative hypothesis for the population of a tissue engineered heart valve by endogenous cells. Key processes include proliferation, differentiation, and mobilization of endothelial progenitor cells within the bone marrow, followed by recruitment in the blood and adhesion to the valve. Subsequently, recruited cells might undergo an epithelial to mesenchymal transdifferentiation within the valve (recapitulating development), followed by differentiation to interstitial cells that ultimately synthesize and remodel the ECM.






HARNESSING THE REPARATIVE POTENTIAL OF CIRCULATING ENDOGENOUS CELLS: UNSEEDED SCAFFOLDS
in-vitro
in-vivo
2
2
in-vivo
3
).
in-vivo
73
149
40
126
3
125
180
98
109
18
165
172
108

23
157
82
138
167
135
137
138
139
13

in-vivo
89
60
 In both cases (SIS and collagen microsponge) there was no thrombus formation, the scaffold was absorbed, and there was endothelialization, parallel smooth muscle cell alignment, elastin, and collagen fibers. These results suggested that the patch promoted in-situ cellularization and regeneration of autologous tissue. However, an important limitation of these studies was that the implanted leaflets and patches were small; cellularization of a large implant may be less efficient.

CLINICAL STUDIES USING ENGINEERED MATRICES AS HEART VALVES
29
 According to the investigators, based on a one-year follow-up, seeded endothelial cells remained on the construct and were fully functional and the construct mechanical strength was maintained. There was no calcification and/or thrombogenesis. However, whether the seeded cells contributed to valve function is yet uncertain.
156
in-vitro
32
et al.
156
140


CHALLENGES FOR FUTURE TRANSLATION TO THE CLINIC
4
TABLE 5.
Critical challenges to clinical translation of heart valve tissue engineering.

Challenges
Strategy for translation


TEHV components and function are complex, heterogeneous and dynamic
Develop guidelines for the pre-implantation characterization of TEHV structure, function and quality

TEHV function depends upon patient response to implantation and integration with the recipient’s tissues more than conventional valve replacement
in-vivo
 monitoring

Individuals differ in the speed and effectiveness of their tissue remodeling
Assess/control patient variability in tissue remodeling capability

Owing to the key role of patient response, animal models may not reliably predict human outcomes
Validate suitable animal models that will test key biological processes and correlate with human outcomes

Remodeling processes after implantation may release or change seeded cells and recruit host cells
Develop tools to monitor the fate of transplanted and endogenous cells (location, function, viability, phenotype)




FIGURE 4.
in-vitro
in-vivo
 models are necessary for understanding key biological processes in tissue engineering and regenerative medicine. These concepts and data can be used to predict and measure patient success and failure. Data from clinical experience further informs the development of appropriate biomarkers, which may result in reassessment of the appropriate characterization parameters.




Numerous steps must be surmounted in the laboratory before heart valve tissue engineered constructs can be made clinically useful. Typical biomaterial-tissue interactions in medical devices, such as thrombosis, infection, and inflammatory interactions, will have to be acceptable. Another important consideration is whether calcification, the major pathologic process in bioprosthetic valve degeneration, will be problematic. Evidence suggests that calcification may not be a major problem as long as polymer or other scaffold is resorbed and/or not intrinsically mineralizable, the interstitial cells are viable, and the ECM is capable of remodeling.
144
 Owing to immunologic considerations, the choice of an animal model for preclinical testing for allogenic or xenogeneic cell-based therapies presents unique challenges.
in-vivo
179
5
11
24
38
91
FIGURE 5.
A hypothesis for inter-individual variability in tissue remodeling. While most individuals will remodel tissue with a usual speed and quality of remodeling, some people will display slow and poor quality of remodeling while others will show fast and better quality of remodeling. Inadequate remodeling could lead to implant failure and its consequences for the patient. The threshold of properties needed for tissue engineered heart valves and the means of conducting post-implantation surveillance of the patient and graft need to consider this variability. Success or failure may be followed and predicted non-invasively.




in-vivo
in-vitro
in-vivo
in-vivo
4
42
39
136
49
175
55
 These biomarkers should correlate directly with success and failure in order to generate surrogate endpoints, namely outcome measurements (such as laboratory assays or imaging results) that substitute for but reflect the mechanism of a significant clinical event or characteristic (such as regurgitation, stenosis, thromboembolism, calcification, infection, or death). Validated surrogate end points could be assessed in an individual patient, in order to predict outcome as early as possible in the patient’s course and influence necessary changes in management.
8
44
57
62
63
In-vivo
19
24
in-vivo
12
105
in-vivo
15
47
111
in-vivo
 analysis without tissue sampling. Such imaging modalities may prove useful in assessing tissue remodeling for heart valve tissue engineering applications.
in-vitro
in-vivo
in-vitro
in-vitro
in-vivo
62
63
in-vivo
51
in-vitro
 stage and then analyzed using molecular imaging to ensure that they differentiate into appropriate cell lineages and that they remain functional and attached to the scaffold over time.
128

Another key need is the development of science-based approaches to the characterization of fabricated/manufactured engineered tissue products in general and heart valves in particular. These will likely include measurement of mechanical properties of the scaffold and the tissue-scaffold complex, characterization of the dynamic cell phenotypes and ECM components, and the evolution of the final manufactured product, including shelf-life, stability, and shipping considerations.

CONCLUSIONS
in-vitro
in-vivo
 preclinical studies.

NOTE ADDED IN PROOF
Several studies relevant to and that became available during final production of this manuscript may interest readers.
Visconti, R.P., Y. Ebihara, A.C. LaRue, P.A. Fleming, T.C. McQuinn, M. Masuya, H. Minamiguchi, R.R. Markwald, M. Ogawa, and C.J. Drake. An invivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ. Res. 98:690–696, 2006.

To test the hypothesis that hematopoietic stem cells (HSC) may be a source of adult valve interstitial cells, single lineage-negative (Lin-), c-kit(+), Sca-l(+), CD34- cells from the bone marrow of mice that ubiquitously express enhanced green fluorescent protein (EGFP) were transplanted into a lethally irradiated congenic non-EGFP mouse. Histological analyses of valve tissue from clonally engrafted recipient mice revealed the presence of numerous EGFP+ cells within host valves, some of which exhibited synthetic properties characteristic of fibroblasts (expression of mRNA for procollagen 1 alpha 1). The cells were shown to be the result of HSC-derived cell differentiation and not fusion with host somatic cells. Together, these findings demonstrate a contribution by HSCs to the adult valve interstitial cell population in mice.
Cao, F., S. Lin, X. Xie, P. Ray, M. Patel, X. Zhang, M. Drukker, S.J. Dylla, A.J. Connolly, X. Chen, I.L. Weissman, S.S. Gambhir, and J.C. Wu. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 113:1005–1014, 2006.

As discussed in the body of the present manuscript, monitoring the trafficking and function of stem cells in vivo remains problematic owing to limitations of conventional histological assays and imaging modalities. A recent study demonstrated a method by which embryonic stem (ES) cells could be stably transduced with a lentiviral vector carrying a novel triple-fusion (TF) reporter gene, tracked by positron emission tomography, and monitored for survival, proliferation, and migration. This imaging platform should have broad applications for basic research and clinical studies on stem cell therapy.
Kiernan, T.J. Endothelial progenitor cells in 2006 – where are we now? Cardiovasc. Pathol. 15:236–239, 2006.

A recent brief review of the current status of endothelial progenitor cells (EPCs), including their role as biomarkers and potential therapeutic applications, may be useful to the reader of the present manuscript. The authors emphasize critical questions relating to the characterization of the biological phenotype of “true” EPCs and the mechanisms of interaction of EPCs with resident cells of the vascular wall.


REFERENCES
1
Aikawa
E.

Whittaker
P.

Farber
M.

Mendelson
K.

Padera
R.

Schoen
F.


Human semilunar cardiac valve remodeling by activated cells from fetus to adult: Implications for postnatal adaptation, valve pathology and tissue engineering
Circulation
2006
113
1344
1352

16534030


2
Anderson
D. G.

Burdick
J. A.

Langer
R.


Materials science. Smart biomaterials
Science
2004
305
1923
1924

15448260


3
Aoki
J.

Serruys
P. W.

van Beusekom
H.

Ong
A. T.

McFadden
E. P.

Sianos
G.

van der Giessen
W. J.

Regar
E.

de Feyter
P. J.

Davis
H. R.

Rowland
S.

Kutryk
M. J.


Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry
J. Am. Coll. Cardiol.
2005
45
1574
1579

15893169


4
Apple
F. S.

Wu
A. H.

Mair
J.

Ravkilde
J.

Panteghini
M.

Tate
J.

Pagani
F.

Christenson
R. H.

Mockel
M.

Danne
O.

Jaffe
A. S.


Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome
Clin. Chem.
2005
51
810
824

15774573


5
Armstrong
E. J.

Bischoff
J.


Heart valve development: Endothelial cell signaling and differentiation
Circ. Res .
2004
95
459
470

15345668


6
Badylak
S. F.


Regenerative medicine approach to heart valve replacement
Circulation
2005
111
2715
2716

15927987


7
Badylak
S. F.

Record
R.

Lindberg
K.

Hodde
J.

Park
K.


Small intestinal submucosa: a substrate for in vitro cell growth
J. Biomater. Sci. Polym.
1998
9
863
878

Badylak, S. F., R. Record, K. Lindberg, J. Hodde, and K. Park. Small intestinal submucosa: a substrate for in vitro cell growth. J. Biomater. Sci. Polym. 9:863–878, 1998. 

8
Basilion
J. P.

Yeon
S.

Botnar
R.


Magnetic resonance imaging: utility as a molecular imaging modality
Curr. Top Dev. Biol.
2005
70
1
33

16338335


9
Beis
D.

Bartman
T.

Jin
S. W.

Scott
I. C.

D’Amico
L. A.

Ober
E. A.

Verkade
H.

Frantsve
J.

Field
H. A.

Wehman
A.

Baier
H.

Tallafuss
A.

Bally-Cuif
L.

Chen
J. N.

Stainier
D. Y.

Jungblut
B.


Genetic and cellular analyses of zebrafish atrioventricular cushion and valve development
Development
2005
132
4193
4204

16107477


10
Bertipaglia
B.

Ortolani
F.

Petrelli
L.

Gerosa
G.

Spina
M.

Pauletto
P.

Casarotto
D.

Marchini
M.

Sartore
S.


Vitalitate Exornatum Succedaneum Aorticum Labore Ingenioso Obtenibitur Project. Cell characterization of porcine aortic valve and decellularized leaflets repopulated with aortic valve interstitial cells: the VESALIO Project (Vitalitate Exornatum Succedaneum Aorticum Labore Ingenioso Obtenibitur)
Ann. Thorac. Surg.
2003
75
1274
1282

12683575


11
Blom
I. E.

van Dijk
A. J.

de Weger
R. A.

Tilanus
M. G.

Goldschmeding
R.


Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms
Mol. Pathol .
2001
54
192
196

11376134


12
Boecker
W.

Bernecker
O. Y.

Wu
J. C.

Zhu
X.

Sawa
T.

Grazette
L.

Rosenzweig
A.

del Monte
F.

Schmidt
U.

Hajjar
R. J.


Cardiac-specific gene expression facilitated by an enhanced myosin light chain promoter
Mol. Imaging
2004
3
69
75

15296671


13
Borschel
G. H.

Huang
Y. C.

Calve
S.

Arruda
E. M.

Lynch
J. B.

Dow
D. E.

Kuzon
W. M.

Dennis
R. G.

Brown
D. L.


Tissue engineering of recellularized small-diameter vascular grafts
Tissue Eng .
2005
11
778
786

15998218


14
Breuer
C. K.

Mettler
B. A.

Anthony
T.

Sales
V. L.

Schoen
F. J.

Mayer
J. E.


Application of tissue-engineering principles toward the development of a semilunar heart valve substitute
Tissue Eng .
2004
10
1725
1736

15684681


15
Brezinski
M. E.


Optical coherence tomography for identifying unstable coronary plaque
Int. J. Cardiol.
2006
107
159
170

Brezinski, M. E. Optical coherence tomography for identifying unstable coronary plaque. Int. J. Cardiol. 107:159–170, 2006. 

16
Butcher
J. T.

Nerem
R. M.


Porcine aortic valve interstitial cells in three-dimensional culture: comparison of phenotype with aortic smooth muscle cells
J. Heart Valve Dis.
2004
13
478
485

15222296


17
Butcher
J. T.

Penrod
A. M.

Garcia
A. J.

Nerem
R. M.


Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments
Arterioscler. Thromb. Vasc. Biol .
2004
24
1429
1434

15117733


18
Ceradini
D. J

Gurtner
G. C.


Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue
Trends Cardiovasc Med.
2005
15
57
63

15885571


19
Chen
J.

Tung
C. H.

Mahmood
U.

Ntziachristos
V.

Gyurko
R.

Fishman
M. C.

Huang
P. L.

Weissleder
R.


In vivo imaging of proteolytic activity in atherosclerosis
Circulation
2002
105
2766
2771

12057992


20
Biomat.
 27:3631–3638, 2006.

21
Davies
P. F.

Passerini
A. G.

Simmons
C. A.


Aortic valve: turning over a new leaf(let) in endothelial phenotypic heterogeneity
Arterioscler Thromb. Vasc. Biol.
2004
24
1331
1333

15297285


22
Dawn
B.

Bolli
R.


Adult bone marrow-derived cells: Regenerative potential, plasticity, and tissue commitment
Basic Res. Cardiol.
2005
100
494
503

16237509


23
Deb
A.

Wang
S. H.

Skelding
K.

Miller
D.

Simper
D.

Caplice
N.


Bone marrow-derived myofibroblasts are present in adult human heart valves
J. Heart Valve Dis.
2005
14
674
678

16245507


24
Deguchi
J.-O.

Aikawa
E.

Libby
P.

Vachon
J. R.

Inada
M.

Krane
S. M.

Whittaker
P.

Aikawa
M.


Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques
Circulation
2005
112
2708
2715

16230484


25
Della Rocca
F.

Sartore
S.

Guidolin
D.

Bertiplaglia
B.

Gerosa
G.

Casarotto
D.

Pauletto
P.


Cell composition of the human pulmonary valve: A comparative study with the aortic valve—The VESALIO project
Ann. Thorac. Surg.
2000
70
1594
1600

11093493


26
Deutsch
M.

Meinhart
J.

Fischlein
T.

Preiss
P.

Zilla
P.


Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience
Surgery
1999
126
847
855

10568184


27
Dimmeler
S.

Zeiher
A. M.

Schneider
M. D.


Unchain my heart: the scientific foundations of cardiac repair
J. Clin. Invest
2005
115
572
583

15765139


28
Dohmen
P. M.

Costa
F.

Lopes
S. V.

Yoshi
S.

Souza
F. P.

Vilani
R.

Costa
M. B.

Konertz
W.


Results of a decellularized porcine heart valve implanted into the juvenile sheep model
Heart Surg. Forum.
2005
8
E100
E104

15769723


29
Dohmen
P. M.

Lembcke
A.

Hotz
H.

Kivelitz
D.

Konertz
W. F.


Ross operation with a tissue-engineered heart valve
Ann. Thorac. Surg.
2002
74
1438
1442

12440590


30
Eisenberg
L. M.

Markwald
R. R.


Molecular regulation of atrioventricular valvuloseptal morphogenesis
Circ. Res.
1995
77
1
6

7788867


31
Eisenberg
L. M.

Moreno
R.

Markwald
R. R.


Multiple stem cell populations contribute to the formation of the myocardium
Ann. N.Y. Acad. Sci .
2005
1047
38
49

16093483


32
Elkins
R. C.

Dawson
P. E.

Goldstein
S.

Walsh
S. P.

Black
K. S.


Decellularized human valve allografts
Ann. Thorac. Surg.
2001
71
S428
S432

11388241


33
Emsley
J. G.

Mitchell
B. D.

Kempermann
G.

Macklis
J. D.


Adult neurogenesis and repair of the adult CNS with neural progenitors, and stem cells
Prog. Neurobiol.
2005
75
321
341

15913880


34
Engelmayr
G. C.

Hildebrand
D. K.

Sutherland
F. W.

Mayer
J. E.

Sacks
M. S.


A novel bioreactor for the dynamic flexural stimulation of tissue engineered heart valve biomaterials
Biomaterials
2003
24
2523
2532

12695079


35
Erez
E.

Kanter
K. R.

Isom
E.

Williams
W. H.

Tam
V. K.


Mitral valve replacement in children
J. Heart Valve Dis.
2003
12
25
29

12578331


36
Eschenhagen
T.

Zimmermann
W. H.


Engineering myocardial tissue
Circ. Res.
2005
97
1220
1231

16339494


37
Eybl
E.

Grimm
M.

Grabenwoger
M.

Bock
P.

Muller
M. M.

Wolner
E.


Endothelial cell lining of bioprosthetic heart valve materials
J. Thorac. Cardiovasc. Surg.
1992
104
763
769

1355151


38
Fedak
P. W. M.

Smookler
D. S.

Kassiri
Z.

Ohno
N.

Leco
K. J.

Verma
S.

Mickle
D. A. G.

Watson
K. L.

Hojilla
C. V.

Cruz
W.

Weisel
R. D.

Li
R.-K.

Khokha
R.


TIMP-3 deficiency leads to dilated cardiomyopathy
Circulation
2004
110
2401
2409

15262835


39
Fernandez
C. A.

Yan
L.

Louis
G.

Yang
J.

Kutok
J. L.

Moses
M. A.


The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients
Clin. Cancer Res.
2005
11
5390
5395

16061852


40
Frazier
O. H.

Baldwin
R. T.

Eskin
S. G.

Duncan
J. M.


Immunochemical identification of human endothelial cells on the lining of a ventricular assist device
Tex Heart Inst. J.
1993
20
78
82

8392881


41
Freed
L. E.

Vunjak-Novakovic
G.

Biron
R. J.

Eagles
D. B.

Lesnoy
D. C.

Barlow
S. K.

Langer
R.


Biodegradable polymer scaffolds for tissue engineering
Biotechnology
1994
12
689
693

7764913


42
Fukuda
D.

Shimada
K.

Tanaka
A.

Kusuyama
T.

Yamashita
H.

Ehara
S.

Nakamura
Y.

Kawarabayashi
T.

Iida
H.

Yoshiyama
M.

Yoshikawa
J.


Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris
Am. J. Cardiol.
2006
97
175
180

16442358


43
Garg
V.

Muth
A. N.

Ransom
J. F.

Schluterman
M. K.

Barnes
R.

King
I. N.

Grossfeld
P. D.

Srivastava
D.


Mutations in NOTCH1 cause aortic valve disease
Nature
2005
437
270
274

16025100


44
Genove
G.

DeMarco
U.

Xu
H.

Goins
W. F.

Ahrens
E. T.


A new transgene reporter for in vivo magnetic resonance imaging
Nat. Med.
2005
11
450
454

15778721


45
George
J.

Afek
A.

Abashidze
A.

Shmilovich
H.

Deutsch
V.

Kopolovich
J.

Miller
H.

Keren
G.


Transfer of Endothelial Progenitor and Bone Marrow Cells Influences Atherosclerotic Plaque Size and Composition in Apolipoprotein E Knockout Mice
Arterioscler. Thromb. Vasc. Biol.
2005
25
2636
2641

16195475


46
Giannoudis
P. V.

Pountos
I.


Tissue regeneration: The past, the present and the future
Injury
2005
36
Suppl.
S2
S5

16288758


47
Int. J. Cardiol.
 107:400–409, 2006.

48
Grayson
A. C.

Voskerician
G.

Lynn
A.

Anderson
J. M.

Cima
M. J.

Langer
R.


Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip
J. Biomater. Sci. Polym. Ed.
2004
15
1281
1304

15559850


49
Grossman
H. B.

Soloway
M.

Messing
E.

Katz
G.

Stein
B.

Kassabian
V.

Shen
Y.


Surveillance for recurrent bladder cancer using a point-of-care proteomic assay
JAMA
2006
295
299
305

16418465


50
Hammermeister
K.

Sethi
G. K.

Henderson
W. G.

Grover
F. L.

Oprian
C.

Rahimtoola
S. H.


Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial
J. Am. Coll. Cardiol.
2000
36
1152
1158

11028464


51
Hill
J. M.

Dick
A. J.

Raman
V. K.

Thompson
R. B.

Yu
Z. X.

Hinds
K. A.

Pessanha
B. S.

Guttman
M. A.

Varney
T. R.

Martin
B. J.

Dunbar
C. E.

McVeigh
E. R.

Lederman
R. J.


Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells
Circulation
2003
108
1009
1014

12912822


52
Hoerstrup
S. P.

Sodian
R.

Daebritz
S.

Wang
J.

Bacha
E. A.

Martin
D. P.

Moran
A. M.

Guleserian
K. J.

Sperling
J. S.

Kaushal
S.

Vacanti
J. P.

Schoen
F. J.

Mayer
J. E.


Functional living trileaflet heart valves grown in vitro
Circulation
2000
102
SIII-44
SIII-49

Hoerstrup, S. P., R. Sodian, S. Daebritz, J. Wang, E. A. Bacha, D. P. Martin, A. M. Moran, K. J. Guleserian, J. S. Sperling, S. Kaushal, J. P. Vacanti, F. J. Schoen, and J. E. Mayer. Functional living trileaflet heart valves grown in vitro. Circulation 102:SIII-44–SIII-49, 2000. 

53
Hollister
S. J.


Porous scaffold design for tissue engineering
Nat. Mater.
2005
4
518
524

16003400


54
Hopkins
R. A.


Tissue engineering of heart valves: decellularized valve scaffolds
Circulation
2005
111
2712
2714

15927986


55
Hoque
M. O.

Topaloglu
O.

Begum
S.

Henrique
R.

Rosenbaum
E.

Van Criekinge
W.

Westra
W. H.

Sidransky
D.


Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects
J. Clin. Oncol.
2005
23
6569
6575

16170165


56
Hristov
M.

Erl
W.

Weber
P. C.


Endothelial progenitor cells: mobilization, differentiation, and homing
Arterioscler. Thromb. Vasc. Biol.
2003
23
1185
1189

12714439


57
Ichikawa
T.

Hogemann
D.

Saeki
Y.

Tyminski
E.

Terada
K.

Weissleder
R.

Chiocca
E. A.

Basilion
J. P.


MRI of transgene expression: correlation to therapeutic gene expression
Neoplasia
2002
4
523
530

12407446


58
Isenberg
B. C.

Williams
C.

Tranquillo
R. T.


Small-diameter artificial arteries engineered in vitro
Circ. Res.
2006
98
25
35

16397155


59
Ishihara
T.

Ferrans
V. J.

Jones
M.

Boyce
S. W.

Roberts
W. C.


Occurrence and significance of endothelial cells in implanted porcine bioprosthetic valves
Am. J. Cardiol.
1981
48
443
454

7270450


60
Iwai
S.

Sawa
Y.

Ichikawa
H.

Taketani
S.

Uchimura
E.

Chen
G.

Hara
M.

Miyake
J.

Matsuda
H.


Biodegradable polymer with collagen microsponge serves as a new bioengineered cardiovascular prosthesis
J. Thorac. Cardiovasc. Surg.
2004
128
472
479

15354111


61
Iwami
Y.

Masuda
H.

Asahara
T.


Endothelial progenitor cells: past, state of the art, and future
J. Cell Mol. Med.
2004
8
488
497

15601577


62
Jaffer
F. A.

Weissleder
R.


Seeing within: molecular imaging of the cardiovascular system
Circ. Res.
2004
94
433
445

15001542


63
Jaffer
F. A.

Weissleder
R.


Molecular imaging in the clinical arena
J. Am. Med. Assoc.
2005
293
855
862

Jaffer, F. A., and R. Weissleder. Molecular imaging in the clinical arena. J. Am. Med. Assoc. 293:855–862, 2005. 

64
Jamieson
W. R.

von Lipinski
O.

Miyagishima
R. T.

Burr
L. H.

Janusz
M. T.

Ling
H.

Fradet
G. J.

Chan
F.

Germann
E.


Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after mitral valve replacement
J. Thorac. Cardiovasc. Surg.
2005
129
1301
1308

15942570


65
Jiang
Y.

Jahagirdar
B. N.

Reinhardt
R. L.

Schwartz
R. E.

Keene
C. D.

Ortiz-Gonzalez
X. R.

Reyes
M.

Lenvik
T.

Lund
T.

Blackstad
M.

Du
J.

Aldrich
S.

Lisberg
A.

Low
W. C.

Largaespada
D. A.

Verfaillie
C. M.


Pluripotency of mesenchymal stem cells derived from adult marrow
Nature
2002
418
41
49

12077603


66
Jockenhoevel
S.

Zund
G.

Hoerstrup
S. P.

Chalabi
K.

Sachweh
J. S.

Demircan
L.

Messmer
B. J.

Turina
M.


Fibrin gel—advantages of a new scaffold in cardiovascular tissue engineering
Eur. J. Cardiothorac. Surg.
2001
19
424
430

11306307


67
Semin. Thorac. Cardiovasc. Surg. Pediatr. Card Surg. Annu.
 176–180, 2005.

68
Kanter
K. R.

Budde
J. M.

Parks
W. J.

Tam
V. K.

Sharma
S.

Williams
W. H.

Fyfe
D. A.


One hundred pulmonary valve replacements in children after relief of right ventricular outflow tract obstruction
Ann. Thorac. Surg.
2002
73
1801
1806

12078772


69
Karageorgiou
V.

Kaplan
D.


Porosity of 3D biomaterial scaffolds and osteogenesis
Biomaterials
2005
26
5474
5491

15860204


70
Kaushal
S.

Amiel
G. E.

Guleserian
K. J.

Shapira
O. M.

Perry
T.

Sutherland
F. W.

Rabkin
E.

Moran
A. M.

Schoen
F. J.

Atala
A.

Soker
S.

Bischoff
J.

Mayer
J. E.


Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo
Nature Med.
2001
7
1035
1040

11533707


71
Kohn, J., S. Abramson, and R. Langer. Bioresorbable and bioerodible materials. In: Biomaterials Science: An Introduction to Materials in Medicine, 2nd Ed., edited by B. D. Ratner, A. S. Hoffman, F. J. Schoen, and J. E. Lemons. Orlando: Academic Press, 2004.

72
Konertz
W.

Dohmen
P. M.

Liu
J.

Beholz
S.

Dushe
S.

Posner
S.

Lembcke
A.

Erdbrugger
W.


Hemodynamic characteristics of the Matrix P decellularized xenograft for pulmonary valve replacement during the Ross operation
J. Heart Valve Dis.
2005
14
78
81

15700440


73
Kumar, V., N. Fausto, and A. Abbas. Robbins and Cotran Pathologic Basis of Disease, 7th Ed. Philadelphia: W. B. Saunders, 2004.

74
Laflamme
M. A.

Murry
C. E.


Regenerating the heart
Nature Biotech.
2005
23
845
855

Laflamme, M. A., and C. E. Murry. Regenerating the heart. Nature Biotech. 23:845–855, 2005. 

75
Lahann
J.

Mitragotri
S.

Tran
T. N.

Kaido
H.

Sundaram
J.

Choi
I. S.

Hoffer
S.

Somorjai
G. A.

Langer
R.


A reversibly switching surface
Science
2003
299
371
374

12532011


76
Langer
R.

Tirrell
D. A.


Designing materials for biology and medicine
Nature
2004
428
487
492

15057821


77
Langer
R.

Vacanti
J. P.


Tissue engineering
Science
1993
260
920
926

8493529


78
Lee
Y. M.

Cope
J. J.

Ackermann
G. E.

Goishi
K.

Armstrong
E. J.

Paw
B. H.

Bischoff
J.


Vascular endothelial growth factor receptor signaling is required for cardiac valve formation in zebrafish
Dev. Dyn.
2006
235
29
37

16170785


79
Lendlein
A.

Langer
R.


Biodegradable, elastic shape-memory polymers for potential biomedical applications
Science
2002
296
1673
1676

11976407


80
Leor
J.

Amsalem
Y.

Cohen
S.


Cells, scaffolds, and molecules for myocardial tissue engineering
Pharmacol. Therapeut.
2005
105
151
163

Leor, J., Y. Amsalem, and S. Cohen. Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol. Therapeut. 105:151–163, 2005. 

81
Leri
A.

Kajstura
J.

Anversa
P.


Cardiac stem cells and mechanisms of myocardial regeneration
Physiol. Rev.
2005
85
1373
1416

16183916


82
Liu
C.

Nath
K. A.

Katusic
Z. S.

Caplice
N. M.


Smooth muscle progenitor cells in vascular disease
Trends Cardiovasc. Med.
2004
14
288
293

15542381


83
Liu
X.

Ma
P. X.


Polymeric scaffolds for bone tissue engineering
Ann. Biomed. Eng.
2004
32
477
486

15095822


84
Lutolf
M. P.

Hubbell
J. A.


Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering
Nat. Biotechnol.
2005
23
47
55

15637621


85
Mann
B. K.

Gobin
A. S.

Tsai
A. T.

Schmedlen
R. H.

West
J. L.


Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering
Biomaterials
2001
22
3045
3051

11575479


86
J. Cell Biochem.
 97:744–754, 2006.

87
Marron
K.

Yacoub
M. H.

Polak
J. M.

Sheppard
M. N.

Fagan
D.

Whitehead
B. F.

de Leval
M. R.

Anderson
R. H.

Wharton
J.


Innervation of human atrioventricular and arterial valves
Circulation
1996
94
368
375

8759078


88
Masters
K. S.

Shah
D. N.

Leinwand
L. A.

Anseth
K. S.


Crosslinked hyaluronan scaffolds as a biologically active carrier for valvular interstitial cells
Biomaterials
2005
26
2517
2525

15585254


89
Matheny
R. G.

Hutchison
M. L.

Dryden
P. E.

Hiles
M. D.

Shaar
C. J.


Porcine small intestine submucosa as a pulmonary valve leaflet substitute
J. Heart Valve Dis.
2000
9
769
774

11128782


90
Mauney
J. R.

Volloch
V.

Kaplan
D. L.


Role of adult mesenchymal stem cells in bone tissue engineering applications: current status and future prospects
Tissue Eng.
2005
11
787
802

15998219


91
Proc. Natl. Acad. Sci.
 USA 95:11792–11797, 1998.

92
Prog. Ped. Card.
 (in press).

93
Merryman, W. D., H. D. Lukoff, R. A. Hopkins, and M. S. Sacks. Aortic valve interstitial cell phenotype and biosynthesis: synergistic effects of cyclic tension and TGF-β1. Proceedings of BIO2006. ASME Summer Bioengineering Conference, 2006.

94
Merryman
W. D.

Youn
I.

Lukoff
H. D.

Krueger
P. M.

Guilak
F.

Hopkins
R. A.

Sacks
M. S.


Correlation between heart valve interstitial cell stiffness and transvalvular pressure: implications for collagen biosynthesis
Am. J. Physiol. Heart Circ. Physiol.
2006
290
H224
H231

16126816


95
Mitchell
R. N.

Jonas
R. A.

Schoen
F. J.


Pathology of explanted cryopreserved allograft heart valves: comparison with aortic valves from orthotopic heart transplants
J. Thorac. Cardiovasc. Surg.
1998
115
118
127

9451054


96
Mol
A.

Driessen
N. J.

Rutten
M. C.

Hoerstrup
S. P.

Bouten
C. V.

Baaijens
F. P.


Tissue engineering of human heart valve leaflets: a novel bioreactor for a strain-based conditioning approach
Ann. Biomed. Eng.
2005
33
1778
1788

16389526


97
Mol
A.

van Lieshout
M. I.

Dam-de Veen
C. G.

Neuenschwander
S.

Hoerstrup
S. P.

Baaijens
F. P.

Bouten
C. V.


Fibrin as a cell carrier in cardiovascular tissue engineering applications
Biomaterials
2005
26
3113
3121

15603806


98
Mouquet
F.

Pfister
O.

Jain
M.

Oikonomopoulos
A.

Ngoy
S.

Summer
R.

Fine
A.

Liao
R.


Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells
Circ Res.
2005
97
1090
1092

16269652


99
Mulholland
D. L.

Gotlieb
A. I.


Cell biology of valvular interstitial cells
Can. J. Cardiol.
1996
12
231
236

8624972


100
Muschler
G. F.

Nakamoto
C.

Griffith
L. G.


Engineering principles of clinical cell-based tissue engineering
J. Bone Joint Surg. Am.
2004
86A
1541
1558

15252108


101
Narita
Y.

Hata
K.

Kagami
H.

Usui
A.

Ueda
M.

Ueda
Y.


Novel pulse duplicating bioreactor system for tissue-engineered vascular construct
Tissue Eng.
2004
10
1224
1233

15363178


102
Nerem
R. M.

Ensley
A. E.


The tissue engineering of blood vessels and the heart
Am. J. Transplant
2004
4
36
42

14871272


103
Niklason
L. E.

Gao
J.

Abbott
W. M.

Hirschi
K. K.

Houser
S.

Marini
R.

Langer
R.


Functional arteries grown in vitro
Science
1999
284
489
493

10205057


104
Nugent
H. M.

Edelman
E. R.


Tissue engineering therapy for cardiovascular disease
Circ. Res.
2003
92
1068
1078

12775655


105
Ogata
T.

Shibamura
H.

Tromp
G.

Sinha
M.

Goddard
K. A.

Sakalihasan
N.

Limet
R.

MacKean
G. L.

Arthur
C.

Sueda
T.

Land
S.

Kuivaniemi
H.


Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms
J. Vasc. Surg.
2005
41
1036
1042

15944607


106
Olson
E. N.


A decade of discoveries in cardiac biology
Nat. Med.
2004
10
467
474

15122248


107
Orlic
D.

Kajstura
J.

Chimenti
S.

Limana
F.

Jakoniuk
I.

Quaini
F.

Nadal-Ginard
B.

Bodine
D. M.

Leri
A.

Anversa
P.


Mobilized bone marrow cells repair the infarcted heart, improving function and survival
Proc. Natl. Acad. Sci.
2001
98
10344
10349

11504914


108
Ota
T.

Sawa
Y.

Iwai
S.

Kitajima
T.

Ueda
Y.

Coppin
C.

Matsuda
H.

Okita
Y.


Fibronectin-hepatocyte growth factor enhances reendothelialization in tissue-engineered heart valve
Ann. Thorac. Surg.
2005
80
1794
1801

16242457


109
Ott
I.

Keller
U.

Knoedler
M.

Gotze
K. S.

Doss
K.

Fischer
P.

Urlbauer
K.

Debus
G.

von Bubnoff
N.

Rudelius
M.

Schomig
A.

Peschel
C.

Oostendorp
R. A.


Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction
FASEB
2005
19
992
994

Ott, I., U. Keller, M. Knoedler, K. S. Gotze, K. Doss, P. Fischer, K. Urlbauer, G. Debus, N. von Bubnoff, M. Rudelius, A. Schomig, C. Peschel, and R. A. Oostendorp. Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction. FASEB 19:992–994, 2005. 

110
Paranya
G.

Vineberg
S.

Dvorin
E.

Kaushal
S.

Roth
S. J.

Rabkin
E.

Schoen
F. J.

Bischoff
J.


Aortic valve endothelial cells undergo TGF-beta-mediated and non-TGF-beta-mediated transdifferentiation in vitro
Am. J. Pathol.
2001
159
1335
1343

11583961


111
Patel
N. A.

Stamper
D. L.

Brezinski
M. E.


Review of the ability of optical coherence tomography to characterize plaque, including a comparison with intravascular ultrasound
Cardiovasc. Intervent. Radiol.
2005
28
1
9

15772720


112
Perry
T. E.

Kaushal
S.

Sutherland
F. W.

Guleserian
K. J.

Bischoff
J.

Sacks
M.

Mayer
J. E.


Bone marrow as a cell source for tissue engineering heart valves
Ann. Thorac. Surg.
2003
75
761
767

12645690


113
Pittenger
M. F.

Martin
B. J.


Mesenchymal stem cells and their potential as cardiac therapeutics
Circ. Res.
2004
95
9
20

15242981


114
Poh
M.

Boyer
M.

Solan
A.

Dahl
S. L.

Pedrotty
D.

Banik
S. S.

McKee
J. A.

Klinger
R. Y.

Counter
C. M.

Niklason
L. E.


Blood vessels engineered from human cells
Lancet
2005
365
2122
2124

15964449


115
Pratt
A. B.

Weber
F. E.

Schmoekel
H. G.

Muller
R.

Hubbell
J. A.


Synthetic extracellular matrices for in situ tissue engineering
Biotechnol. Bioeng.
2004
86
27
36

15007838


116
Prockop
D. J.


Marrow stromal cells as stem cells for nonhematopoietic tissues
Science
1997
276
71
74

9082988


117
Rabkin
E.

Aikawa
M.

Stone
J. R.

Fukumoto
Y.

Libby
P.

Schoen
F. J.


Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves
Circulation
2001
104
2525
2532

11714645


118
Rabkin
E.

Hoerstrup
S. P.

Aikawa
M.

Mayer
J. E.

Schoen
F. J.


Evolution of cell phenotype and extracellular matrix in tissue-engineered heart valves during in vitro maturation and in vivo remodeling
J. Heart Valve Dis.
2002
11
308
314

12056720


119
Rabkin
E.

Schoen
F. J.


Cardiovascular tissue engineering
Cardiovasc. Pathol.
2002
11
305
317

12459430


120
Rabkin-Aikawa
E.

Aikawa
M.

Farber
M.

Kratz
J. R.

Garcia-Cardena
G.

Kouchoukos
N. T.

Mitchell
M. B.

Jonas
R. A.

Schoen
F. J.


Clinical pulmonary autograft valves: pathologic evidence of adaptive remodeling in the aortic site
J. Thorac. Cardiovasc. Surg.
2004
128
552
561

15457156


121
Rabkin-Aikawa
E.

Farber
M.

Aikawa
M.

Schoen
F. J.


Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves
J. Heart Valve Dis.
2004
13
841
847

15473488


122
Rabkin-Aikawa
E.

Mayer
J. E.

Schoen
F. J.


Heart valve regeneration
Adv. Biochem. Eng. Biotechnol.
2005
94
141
179

15915872


123
Radisic
M.

Park
H.

Shing
H.

Consi
T.

Schoen
F. J.

Langer
R.

Freed
L. E.

Vunjak-Novakovic
G.


Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds
Proc. Natl. Acad. Sci. USA
2004
101
18129
18134

15604141


124
Radisky
D. C.


Epithelial-mesenchymal transition
J. Cell Sci.
2005
118
4325
4326

16179603


125
Rafii
S.

Lyden
D.


Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration
Nat. Med.
2003
9
702
712

12778169


126
Rafii
S.

Oz
M. C.

Seldomridge
J. A.

Ferris
B.

Asch
A. S.

Nachman
R. L.

Shapiro
F.

Rose
E. A.

Levin
H. R.


Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices
Ann. Thorac. Surg.
1995
60
1627
1632

8787455


127
Rahimtoola
S. H.


Choice of prosthetic heart valve for adult patients
J. Am. Coll. Cardiol.
2003
41
893
904

12651032


128
Rahimtoola
S. H.


The next generation of prosthetic heart valves needs a proven track record of patient outcomes at > or =15 to 20 years
J. Am. Coll. Cardiol.
2003
42
1720
1721

14642677


129
Ramamurthi
A.

Vesely
I.


Evaluation of the matrix-synthesis potential of crosslinked hyaluronan gels for tissue engineering of aortic heart valves
Biomaterials
2005
26
999
1010

15369688


130
Ratner
B. D.

Bryant
S. J.


Biomaterials: Where we have been and where we are going
Ann. Rev. Biomed. Eng.
2004
6
41
75

15255762


131
Rieder
E.

Seebacher
G.

Kasimir
M.

Eichmair
E.

Winter
B.

Dekan
B.

Wolner
E.

Simon
P.

Weigel
G.


Tissue engineering of heart valves: decellularized porcine and human valve scaffolds differ importantly in residual potential to attract monocytic cells
Circulation
2005
111
2792
2797

15911701


132
Robinson
K. A.

Li
J.

Mathison
M.

Redkar
A.

Cui
J.

Chronos
N. A.

Matheny
R. G.

Badylak
S. F.


Extracellular matrix scaffold for cardiac repair
Circulation
2005
112
I135
I143

16159805


133
Roeder
R. A.

Lantz
G. C.

Geddes
L. A.


Mechanical remodeling of small-intestine submucosa small-diameter vascular grafts—A preliminary report
Biomed. Instrum. Technol.
2001
35
110
120

11383308


134
Ross
J. J.

Tranquillo
R. T.


ECM gene expression correlates with in vitro tissue growth and development in fibrin gel remodeled by neonatal smooth muscle cells
Matrix Biol.
2003
22
477
490

14667840


135
Thromb. Vasc. Biol.
 24:1977–1979.

136
Roy
R.

Wewer
U. M.

Zurakowski
D.

Pories
S. E.

Moses
M. A.


ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage
J. Biol. Chem.
2004
279
51323
51330

15381692


137
Saiura
A.

Sata
M.

Hirata
Y.

Nagai
R.

Makuuchi
M.


Circulating smooth muscle progenitor cells contribute to atherosclerosis
Nat. Med.
2001
7
382
383

11283635


138
Sata
M.

Fukuda
D.

Tanaka
K.

Kaneda
Y.

Yashiro
H.

Shirakawa
I.


The role of circulating precursors in vascular repair and lesion formation
J. Cell Mol. Med.
2005
9
557
568

16202205


139
Sata
M.

Saiura
A.

Kunisato
A.

Tojo
A.

Okada
S.

Tokuhisa
T.

Hirai
H.

Makuuchi
M.

Hirata
Y.

Nagai
R.


Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis
Nat. Med.
2002
8
403
409

11927948


140
Sayk
F.

Bos
I.

Schubert
U.

Wedel
T.

Sievers
H. H.


Histopathologic findings in a novel decellularized pulmonary homograft: an autopsy study
Ann. Thorac. Surg.
2005
79
1755
1758

15854972


141
Schenke-Layland
K.

Riemann
I.

Opitz
F.

Konig
K.

Halbhuber
K. J.

Stock
U. A.


Comparative study of cellular and extracellular matrix composition of native and tissue engineered heart valves
Matrix Biol.
2004
23
113
125

15246110


142
Schmitt-Graff
A.

Desmouliere
A.

Gabbiani
G.


Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity
Virchows Arch.
1994
425
3
24

7921410


143
Schoen
F. J.


Aortic valve structure-function correlations: role of elastic fibers no longer a stretch of the imagination
J. Heart Valve Dis.
1997
6
1
6

9044068


144
J. Thorac. Cardiovasc. Surg.
 88:208–216, 1984.

145
Schoen
F. J.


Future directions in tissue heart valves: Impact of recent insights from biology and pathology
J. Heart Valve Dis.
1999
8
350
358

10461233


146
Schoen, F. J. Pathology of heart valve substitution with mechanical and tissue prostheses. In: Cardiovascular Pathology 3rd Ed., edited by M. D. Silver, A. I. Gotlieb, and F. J. Schoen. New York: Churchill Livingstone, 2001, pp. 629–677.

147
Schoen, F. J., and W. D. Edwards. Valvular heart disease: General principles and stenosis. In: Cardiovascular Pathology 3rd Ed., edited by M. D. Silver, A. I. Gotlieb, and F. J. Schoen. New York: Churchill Livingstone, 2001, pp. 402–405.

148
Schurch
W.

Seemayer
T. A.

Gabbiani
G.


The myofibroblast: a quarter century after its discovery
Am. J. Surg. Pathol.
1998
22
141
147

9500214


149
Shi
Q.

Rafii
S.

Wu
M. H.

Wijelath
E. S.

Yu
C.

Ishida
A.

Fujita
Y.

Kothari
S.

Mohle
R.

Sauvage
L. R.

Moore
M. A.

Storb
R. F.

Hammond
W. P.


Evidence for circulating bone marrow-derived endothelial cells
Blood
1998
92
362
367

9657732


150
Shi
Y.

Ramamurthi
A.

Vesely
I.


Towards tissue engineering of a composite aortic valve
Biomed. Sci. Instrum.
2002
38
35
40

12085630


151
Shi
Y.

Vesely
I.


Fabrication of mitral valve chordae by directed collagen gel shrinkage
Tissue Eng.
2003
9
1233
1242

14670111


152
Shinoka
T.

Breuer
C. K.

Tanel
R. E.

Zund
G.

Miura
T.

Ma
P. X.

Langer
R.

Vacanti
J. P.

Mayer
J. E.


Tissue engineering heart valves: valve leaflet replacement study in a lamb model
Ann. Thorac. Surg.
1995
60
S513
S516

8604922


153
Shinoka
T.

Ma
P. X.

Shum-Tim
D.

Breuer
C. K.

Cusick
R. A.

Zund
G.

Langer
R.

Vacanti
J. P.

Mayer
J. E.


Tissue-engineered heart valves. Autologous valve leaflet replacement study in a lamb model
Circulation
1996
94
II164
II168

8901739


154
Silva
G. A.

Czeisler
C.

Niece
K. L.

Beniash
E.

Harrington
D. A.

Kessler
J. A.

Stupp
S. I.


Selective differentiation of neural progenitor cells by high-epitope density nanofibers
Science
2004
303
1352
1355

14739465


155
Simmons
C. A.

Grant
G. R.

Manduchi
E.

Davies
P. F.


Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves
Circ. Res.
2005
96
792
799

15761200


156
Simon
P.

Kasimir
M. T.

Seebacher
G.

Weigel
G.

Ullrich
R.

Salzer-Muhar
U.

Rieder
E.

Wolner
E.


Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients
Eur. J. Cardiothorac. Surg.
2003
23
1002
1006

12829079


157
Simper
D.

Stalboerger
P. G.

Panetta
C. J.

Wang
S.

Caplice
N. M.


Smooth muscle progenitor cells in human blood
Circulation
2002
106
1199
1204

12208793


158
Sodian
R.

Lemke
T.

Fritsche
C.

Hoerstrup
S. P.

Fu
P.

Potapov
E. V.

Hausmann
H.

Hetzer
R.


Tissue-engineering bioreactors: a new combined cell-seeding and perfusion system for vascular tissue engineering
Tissue Eng.
2002
8
863
870

12459065


159
Spina
M.

Ortolani
F.

Messlemani
A. E.

Gandaglia
A.

Bujan
J.

Garcia-Honduvilla
N.

Vesely
I.

Gerosa
G.

Casarotto
D.

Petrelli
L.

Marchini
M.


Isolation of intact aortic valve scaffolds for heart-valve bioprostheses: extracellular matrix structure, prevention from calcification, and cell repopulation features
J. Biomed. Mater. Res.
2003
67
1338
1350

Spina, M., F. Ortolani, A. E. Messlemani, A. Gandaglia, J. Bujan, N. Garcia-Honduvilla, I. Vesely, G. Gerosa, D. Casarotto, L. Petrelli, and M. Marchini. Isolation of intact aortic valve scaffolds for heart-valve bioprostheses: extracellular matrix structure, prevention from calcification, and cell repopulation features. J. Biomed. Mater. Res. 67:1338–1350, 2003. 

160
Srivastava
D.

Olson
E. N.


A genetic blueprint for cardiac development
Nature
2000
407
221
226

11001064


161
Stegemann
J. P.

Nerem
R. M.


Phenotype modulation in vascular tissue engineering using biochemical and mechanical stimulation
Ann. Biomed. Eng.
2003
31
391
402

12723680


162
Steinhoff
G.

Stock
U.

Karim
N.

Mertsching
H.

Timke
A.

Meliss
R.

Pethig
K.

Haverich
A.

Bader
A.


Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits in vivo restoration of valve tissue
Circulation
2000
102
III-50
III-55

11082362


163
Stock
U. A.

Schenke-Layland
K.


Performance of decellularized xenogeneic tissue in heart valve replacement
Biomaterials
2006
27
1
2

16026824


164
Sutherland
F. W. H.

Perry
T. E.

Yu
Y.

Sherwood
M. C.

Rabkin
E.

Masuda
Y.

Garcia
G. A.

McLellan
D. L.

Engelmayr
G. C.

Sacks
M. S.

Schoen
F. J.

Mayer
J. E.


From stem cells to viable autologous semilunar heart valves
Circulation
2005
111
2783
2791

15927990


165
Szmitko
P. E.

Fedak
P. W.

Weisel
R. D.

Stewart
D. J.

Kutryk
M. J.

Verma
S.


Endothelial progenitor cells: new hope for a broken heart
Circulation
2003
107
3093
3100

12821589


166
Tamariz
E.

Grinnell
F.


Modulation of fibroblast morphology and adhesion during collagen matrix remodeling
Mol. Biol. Cell
2002
13
3915
3929

12429835


167
Tanaka
K.

Sata
M.

Fukuda
D.

Suematsu
Y.

Motomura
N.

Takamoto
S.

Hirata
Y.

Nagai
R.


Age-associated aortic stenosis in apolipoprotein E-deficient mice
J. Am. Coll. Cardiol.
2005
46
134
141

15992647


168
Taylor
P. M.

Allen
S. P.

Yacoub
M. H.


Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin
J. Heart Valve Dis.
2000
9
150
158

10678389


169
Taylor
P. M.

Batten
P.

Brand
N. J.

Thomas
P. S.

Yacoub
M. H.


The cardiac valve interstitial cell
Int. J. Biochem. Cell. Biol.
2003
35
113
118

12479860


170
Tranquillo
R. T.

Durrani
M. A.

Moon
A. G.


Tissue engineering science: consequences of cell traction force
Cytotechnology
1992
10
225
250

1369238


171
Tranquillo, R., T. Girton, and M. Neidert. Tissue Equivalent Approach to a Tissue Engineered Cardiovascular Valve. Minneapolis: Regents of the University of Minnesota; 2003.

172
Urbich
C.

Aicher
A.

Heeschen
C.

Dernbach
E.

Hofmann
W. K.

Zeiher
A. M.

Dimmeler
S.


Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells
J. Mol. Cell Cardiol.
2005
39
733
742

16199052


173
Urbich
C.

Dimmeler
S.


Endothelial progenitor cells: characterization and role in vascular biology
Circ. Res.
2004
95
343
353

15321944


174
Van den Hoff
M. J.

Kruithof
B. P.

Moorman
A. F.

Markwald
R. R.

Wessels
A.


Formation of myocardium after the initial development of the linear heart tube
Dev. Biol.
2001
240
61
76

11784047


175
Van Le
T. S.

Miller
R.

Barder
T.

Babjuk
M.

Potter
D. M.

Getzenberg
R. H.


Highly specific urine-based marker of bladder cancer
Urology
2005
66
1256
1260

16360453


176
Vesely
I.


Heart valve tissue engineering
Circ. Res.
2005
97
743
755

16224074


177
Walker
G. A.

Masters
K. S.

Shah
D. N.

Anseth
K. S.

Leinwand
L. A.


Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease
Circ. Res.
2004
95
253
260

15217906


178
Weinberg
C. B.

Bell
E.


A blood vessel model constructed from collagen and cultured vascular cells
Science
1986
231
397
400

2934816


179
Weinshilboum
R.


Inheritance and drug response
N. Engl. J. Med.
2003
348
529
537

12571261


180
Werner
N.

Kosiol
S.

Schiegl
T.

Ahlers
P.

Walenta
K.

Link
A.

Bohm
M.

Nickenig
G.


Circulating endothelial progenitor cells and cardiovascular outcomes
N. Engl. J. Med.
2005
353
999
1007

16148285


181
Williams
C.

Wick
T. M.


Perfusion bioreactor for small diameter tissue-engineered arteries
Tissue Eng.
2004
10
930
941

15265311


182
Wood
J. D.

Simmons-Byrd
A.

Spievack
A. R.

Badylak
S. F.


Use of a particulate extracellular matrix bioscaffold for treatment of acquired urinary incontinence in dogs
J. Am. Vet. Med. Assoc.
2005
226
1095
1097

15825734


183
Wu
X.

Huang
L.

Zhou
Q.

Song
Y.

Li
A.

Jin
J.

Cui
B.


Mesenchymal stem cells participating in ex vivo endothelium repair and its effect on vascular smooth muscle cells growth
Int. J. Cardiol.
2005
105
274
282

16274768


184
Wu
X.

Rabkin-Aikawa
E.

Guleserian
K. J.

Perry
T. E.

Masuda
Y.

Sutherland
F. W.

Schoen
F. J.

Mayer
J. E.

Bischoff
J.


Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells
Am. J. Physiol. Heart Circ. Physiol.
2004
287
H480
H487

15277191


185
Yacoub
M. H.

Cohn
L. H.


Novel approaches to cardiac valve repair: from structure to function: Part I
Circulation
2004
109
942
950

14993146


186
Yang
J.

Yamato
M.

Kohno
C.

Nishimoto
A.

Sekine
H.

Fukai
F.

Okano
T.


Cell sheet engineering: recreating tissues without biodegradable scaffolds
Biomaterials
2005
26
6415
6422

16011847


187
Ye
Q.

Zund
G.

Benedikt
P.

Jockenhoevel
S.

Hoerstrup
S. P.

Sakyama
S.

Hubbell
J. A.

Turina
M.


Fibrin gel as a three dimensional matrix in cardiovascular tissue engineering
Eur. J. Cardiothorac. Surg.
2000
17
587
591

10814924


188
Zund
G

Breuer
C. K.

Shinoka
T.

Ma
P. X.

Langer
R.

Mayer
J. E.

Vacanti
J. P.


The in vitro construction of a tissue engineered bioprosthetic heart valve
Eur. J. Cardiothorac. Surg.
1997
11
493
497

9105814





